Press release
Chronic Hepatitis B (CHB) Market Set to Witness Significant Growth by 2025-2034
Chronic Hepatitis B (CHB) Market
Chronic Hepatitis B (CHB) is a serious viral infection of the liver caused by the hepatitis B virus (HBV). It remains a major global public health challenge, affecting nearly 300 million people worldwide. CHB can lead to cirrhosis, liver failure, and hepatocellular carcinoma (HCC), making it one of the leading causes of liver-related morbidity and mortality.
While effective vaccines exist for prevention, there is no universal cure for chronic infection. Current therapies - primarily nucleos(t)ide analogs (NAs) and interferons - focus on viral suppression rather than eradication. However, with new drug classes, immune modulators, and gene-editing technologies under development, the CHB market is on the brink of transformation.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71722
Market Overview
The global Chronic Hepatitis B (CHB) market was valued at USD 5.4 billion in 2024 and is projected to reach USD 9.8 billion by 2034, growing at a CAGR of 6.2% during the forecast period.
Key Highlights
• Market Size 2024: Estimated at USD 5.4 billion
• Forecast 2034: Expected to reach USD 9.8 billion
• CAGR (2025-2034): 6.2%
Market Drivers
• Rising prevalence of chronic HBV infection, particularly in Asia-Pacific and Africa.
• Growing adoption of antiviral therapies to prevent progression to cirrhosis and liver cancer.
• Expansion of global vaccination and screening programs.
• Strong pipeline of immune modulators, siRNA drugs, and therapeutic vaccines.
Market Challenges
• Lack of curative therapies; current treatments are lifelong.
• High disease burden in regions with limited healthcare access.
• Stigma associated with hepatitis B reduces patient diagnosis and treatment rates.
Leading Players
Key companies active in the CHB market include Gilead Sciences, Johnson & Johnson (Janssen), Bristol Myers Squibb, GlaxoSmithKline, Arrowhead Pharmaceuticals, Alnylam Pharmaceuticals, Vir Biotechnology, Arbutus Biopharma, Roche, and Novartis AG.
Segmentation Analysis
By Product
• Nucleos(t)ide Analogs (Tenofovir, Entecavir, Others)
• Interferon Therapy
• siRNA-Based Therapies
• Immune Modulators
• Therapeutic Vaccines
• Gene Editing/Gene Silencing Candidates
By Technology
• Oral Therapy
• Injectable Therapy
• Gene Editing & RNAi Platforms
By End Use
• Hospitals
• Specialty Clinics
• Research Institutes
• Homecare Settings
By Application
• Viral Suppression
• Liver Disease Management (Cirrhosis, HCC Prevention)
• Curative Therapies (Pipeline Candidates)
Summary:
The market is currently dominated by oral nucleos(t)ide analogs, but future growth will be fueled by siRNA-based therapies, therapeutic vaccines, and immune modulators. The shift from viral suppression to curative intent is expected to redefine long-term market dynamics.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/71722/chronic-hepatitis-b-market
Regional Analysis
• North America
Holds a major share, driven by robust healthcare infrastructure, high diagnosis rates, and adoption of advanced antivirals. The U.S. leads with active clinical trials in RNAi and immune-modulating drugs.
• Europe
Second-largest market, supported by strong healthcare systems and reimbursement policies. Countries like Germany, the UK, and France lead in access to advanced therapies.
• Asia-Pacific
Accounts for the highest patient population, with China and India bearing the largest HBV burden. Government programs for vaccination and screening, along with growing R&D, position the region as the fastest-growing market.
• Middle East & Africa
High prevalence rates, particularly in sub-Saharan Africa. Limited infrastructure and affordability issues restrict advanced therapy adoption, though international health partnerships are expanding access.
• Latin America
Emerging opportunities in Brazil and Mexico, supported by government vaccination programs and international collaborations.
Regional Summary:
While North America and Europe dominate current revenues, Asia-Pacific represents the largest patient base and fastest-growing region, offering significant opportunities for companies investing in accessible and innovative therapies.
Market Dynamics
Key Growth Drivers
• Expanding global vaccination and screening initiatives.
• Rapid development of siRNA and immune-modulating therapies.
• Rising investment in curative HBV research.
• Increasing awareness through global health organizations and patient advocacy.
Key Challenges
• Current therapies are non-curative and require lifelong adherence.
• High unmet needs in low-resource settings.
• Stigma and lack of awareness continue to delay treatment initiation.
Latest Market Trends
• Clinical trials for therapeutic vaccines and siRNA-based drugs showing strong efficacy.
• Growing focus on combination therapies to achieve functional cure.
• Expansion of AI-driven drug discovery in HBV treatment pipelines.
• Partnerships between pharma companies and NGOs to broaden treatment access.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71722
Competitor Analysis
Major Players
• Gilead Sciences - Market leader with tenofovir-based antivirals.
• Johnson & Johnson (Janssen) - Strong portfolio in immune modulators.
• Bristol Myers Squibb - Developer of entecavir and other antivirals.
• GlaxoSmithKline - Active in therapeutic vaccine development.
• Arrowhead Pharmaceuticals - Advancing RNAi-based HBV therapies.
• Alnylam Pharmaceuticals - Focused on RNA interference platforms.
• Vir Biotechnology - Collaborating on HBV immune-modulating treatments.
• Arbutus Biopharma - Early-stage research in siRNA therapies.
• Roche - Expanding presence in liver disease biologics.
• Novartis AG - Diversifying rare disease and viral infection portfolio.
Competitive Landscape Summary:
The CHB market is undergoing a paradigm shift. While established players like Gilead and BMS dominate antivirals, biotech innovators such as Arrowhead, Alnylam, and Vir Biotechnology are pushing toward curative approaches. Strategic collaborations, licensing deals, and clinical trial accelerations are shaping the future competitive environment.
Conclusion
The Chronic Hepatitis B (CHB) market is projected to grow from USD 5.4 billion in 2024 to USD 9.8 billion by 2034, at a CAGR of 6.2%. The next decade will see a transition from lifelong viral suppression therapies to curative and immune-modulating solutions.
While challenges such as affordability, stigma, and infrastructure gaps persist, global initiatives and pharmaceutical innovation are expected to bridge these barriers.
Outlook:
North America and Europe remain key revenue drivers, but Asia-Pacific represents the largest and fastest-growing opportunity, given its high disease burden. Companies that successfully deliver curative, affordable, and patient-friendly therapies will lead the market through 2034 and beyond.
This report is also available in the following languages : Japanese (慢性B型肝炎市場), Korean (만성 B형 간염 시장), Chinese (慢性乙型肝炎市场), French (Marché de l'hépatite B chronique), German (Markt für chronische Hepatitis B), and Italian (Mercato dell'epatite B cronica), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71722
Our More Reports:
Asia-Pacific Hernia Repair Devices Market
https://exactitudeconsultancy.com/reports/72330/asia-pacific-hernia-repair-devices-market
North America Hernia Repair Devices Market
https://exactitudeconsultancy.com/reports/72331/north-america-hernia-repair-devices-market
EU5 Gastric Bands and Balloons Market
https://exactitudeconsultancy.com/reports/72332/eu5-gastric-bands-and-balloons-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Hepatitis B (CHB) Market Set to Witness Significant Growth by 2025-2034 here
News-ID: 4177647 • Views: …
More Releases from Exactitude Consultancy
Blockbuster Drugs Facing Patent Cliffs Market Size, Forecast, and CAGR 6.1%
Introduction
The pharmaceutical industry is entering one of its most critical and transformative decades as multiple blockbuster drugs worth hundreds of billions in annual sales approach their patent expirations. Known as the "patent cliff", this phenomenon represents both a major revenue risk for originator companies and a massive opportunity for biosimilar and generic drug manufacturers.
According to Exactitude Consultancy, the Global Blockbuster Drugs on Patent Cliffs Market is projected to reach USD…
Quarterly Catalyst Monitor - Q3 2025 Market Outlook
Introduction
The Q3 2025 pharmaceutical and biotechnology landscape has emerged as one of the most eventful quarters in recent years, marked by record drug approvals, strategic mergers and acquisitions (M&A), and breakthrough clinical milestones across multiple therapeutic areas. With the rapid pace of medical innovation, evolving regulatory frameworks, and accelerating adoption of digital and AI-based drug development tools, Q3 2025 showcased the industry's remarkable adaptability and forward momentum.
According to Exactitude Consultancy,…
Assisted Living Technologies Market Forecast to Reach USD 152.8 Billion by 2034, …
Introduction
The global population is aging faster than ever, creating new challenges and opportunities for healthcare systems, caregivers, and technology providers. As people live longer, there is a growing demand for solutions that enable independent living, safety, and comfort without compromising quality of life. Enter the assisted living technologies market - a rapidly evolving segment at the intersection of healthcare, digital innovation, and home automation.
According to Exactitude Consultancy, the Global Assisted…
Medical Transcription Software Market Forecast to Reach USD 9.48 Billion by 2034 …
Introduction
The digital transformation of healthcare has redefined how clinical data is captured, stored, and analyzed. One of the critical components of this transformation is medical transcription software, which converts voice-recorded reports dictated by healthcare professionals into text format - ensuring accurate, timely, and compliant medical documentation.
According to Exactitude Consultancy, the Global Medical Transcription Software Market is expected to reach USD 9.48 billion by 2034, growing at a CAGR of 7.6%…
More Releases for CHB
Chronic Hepatitis B (CHB) market is expected to reach USD 9.8 billion by 2034
Chronic Hepatitis B (CHB) is a serious liver infection caused by the hepatitis B virus (HBV) that persists for more than six months. It can lead to cirrhosis, liver failure, and hepatocellular carcinoma (HCC) if left untreated. HBV affects nearly 300 million people worldwide, making it a major global health burden.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71733
While vaccines prevent new infections, millions remain chronically infected. Current therapies…
Chronic Hepatitis B (CHB) Market Set for Rapid Growth
Chronic hepatitis B is a serious viral infection that leads to liver inflammation and can result in severe liver damage. The hepatitis B virus (HBV) primarily spreads through contaminated blood. Diagnosis involves several tests, including antibody tests, genotype tests, and viral load tests. Treatment options include antiviral drugs and immune modulators.
𝐆𝐞𝐭 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.alliedmarketresearch.com/request-sample/A31523
Key Market Drivers
• Increased Blood Transfusion Rates: The rise in blood transfusions necessitates…
Canned Fruits Market Is Booming Worldwide | Kronos, Acroyali, CHB Group
The "Canned Fruits Market" intelligence report, just published by USD Analytics Market, covers a micro-level study of important market niches, product offers, and sales channels. to determine market size, potential, growth trends, and competitive environment, the Canned Fruits Market provides dynamic views. Both primary and secondary sources of data were used to generate the research, which has both qualitative and quantitative depth. Several of the major figures the study featured…
Chronic Hepatitis B (CHB) Market Opportunities, Share, & Analysis by 2031
Hepatitis B is a viral infection that causes liver inflammation and damage. Inflammation is swelling that occurs when tissues of the body become injured or infected. Inflammation can damage organs. Chronic hepatitis B is a long-lasting infection. According to National Institutes of Health (NIH), about 90% of infants infected with hepatitis B develop a chronic infection. About 25 to 50% of children infected between the ages of 1 and 5…
Canned Food Market Trends by Leading Key Players Kraft Heinz, Nestl, JBS, CHB G …
Key findings of the Study:
The canned food market was valued at $ 91.4 billion in 2018 and is estimated to reach $124.8 billion by 2026, growing at a CAGR of 3.9% during the forecast period.
By type, the organic segment is estimated to witness the fastest growth, registering a CAGR of 6.4% during the forecast period.
In 2018, by distribution channel, the supermarket/hypermarket segment held the highest share, accounting for one third…
Canned foods Market Projected to reach $124.8 billion by 2026 - Campbell Soup Co …
Canned foods are the food products that are preserved by sterilizing and sealing them in airtight containers. Canning of food products is done to extend their shelf life, coupled with high quality and high nutritional value. The global canned food market was valued at $91.4 billion in 2018 and is anticipated to reach $124.8 billion by 2026, with a CAGR of 3.9% during the forecast period. Canned food is available…
